1 |
Akl E, Muti P, Schunemann H (2008). Anticoagulation in patients with cancer: an overview of reviews. Pol Arch Med Wewn, 118, 183-93.
|
2 |
Albores-Saavedra J, Henson D,Sobin L (1992). The WHO histological classification of tumors of the gallbladder and extrahepatic bile ducts. Cancer, 70, 410-4.
DOI
ScienceOn
|
3 |
Andrea C, Francesco C (2003). Squamous-cell and non-squamous-cell carcinomas of the gallbladder have different risk factors. Lancet Oncol, 4, 393.
|
4 |
Bergman A, Ruiz van Haperen V, Veerman G, et al (1996). Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res, 2, 521.
|
5 |
Charoentum C, Thongprasert S, Chewaskulyong B, et al (2007). Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholanglocarcinoma. World J Gastroenterol, 13, 2852-4.
|
6 |
Comella P, Palmieri G, Lorusso V, et al (1996). Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies. Eur J Cancer, 32, 1719-26.
DOI
ScienceOn
|
7 |
Crino L, Scagliotti G, Marangolo M, et al (1997). Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol, 15, 297.
|
8 |
Delbaldo C, Laurent A, Grenier J, et al (2009). Management of biliary bract carcinomas. Revue du Praticien, 59, 469-73.
|
9 |
De Groen P, Gores G, LaRusso N, et al (1999). Biliary tract cancers. New Engl J Med, 341, 1368.
DOI
ScienceOn
|
10 |
Doval D, Sekhon J, Gupta S, et al (2004). A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Brit J Cancer, 90, 1516-20.
DOI
ScienceOn
|
11 |
Ducreux M, Rougier P, Fandi A, et al (1998). Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol, 9, 653.
DOI
ScienceOn
|
12 |
Eng C, Ramanathan RK, Wong MK, et al (2004). A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol, 27, 565-9.
DOI
ScienceOn
|
13 |
Furuse J, Okusaka T, Bridgewater J, et al (2011). Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. Crit Rev Oncol Hematol, 80, 31-9.
DOI
ScienceOn
|
14 |
Gallardo J, Fodor M, Gamargo C, et al (1998). Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma. Cancer, 83, 2419-20.
DOI
|
15 |
Gallardo J, Rubio B, Fodor M, et al (2001). A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol, 12, 1403.
DOI
ScienceOn
|
16 |
Gebbia V, Majello E, Testa A, et al (1996). Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule: Results of a multicenter study of the Southern Italy Oncology Group (GOIM). Cancer, 78, 1300-7.
DOI
|
17 |
Giuliani F, Gebbia V, Maiello E, et al (2006). Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol, 17, vii73-7.
DOI
ScienceOn
|
18 |
Goldstein D, Gainford M, Brown C, et al (2011). Fixed-dose-rate gemcitabine combined with cisplatin in patients. with inoperable biliary tract carcinomas. Cancer Chemother Pharmacol, 67, 519-25.
DOI
ScienceOn
|
19 |
Heinrich S, Sch fer M, Weber A, et al (2008). Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg, 248, 1014.
DOI
ScienceOn
|
20 |
Hitt R, Castellano D, Hidalgo M, et al (1998). Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck. Ann Oncol, 9, 1347.
DOI
ScienceOn
|
21 |
Higgins JP, Green S (2009). Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2009]. http://www.cochrane-handbook.org/ (accessed 16 June 2010) edition. The Cochrane Collaboration.
|
22 |
Kim S, Park J, Lee J, et al (2006). A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer, 106, 1339-46.
DOI
ScienceOn
|
23 |
Levy AD, Murakata LA, Rohrmann CA Jr (2001). Gallbladder carcinoma: radiologic-pathologic correlation. Radiographics, 21, 295-314.
DOI
ScienceOn
|
24 |
Lee G, Kang J, Kim H, et al (2006). Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. Am J Clin Oncol, 29, 127.
DOI
ScienceOn
|
25 |
Lee J, Kim T, Lee M, et al (2008). Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemoth Pharmacol, 61, 47-52.
|
26 |
Lin MH, Chen JS, Chen HH, et al (2003). A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy, 49, 154-8.
DOI
ScienceOn
|
27 |
Meyerhardt J, Zhu A, Stuart K, et al (2008). Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Digest Dis Sci, 53, 564-70.
DOI
|
28 |
Metzger J, Sauerbruch T, Ko Y, et al (1998). Phase II study with gemcitabine in gallbladder and biliary tract carcinomas. Onkologie, 21, 232-4.
DOI
ScienceOn
|
29 |
Okusaka T, Ishii H, Funakoshi A, et al (2006). Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemoth Pharmacol, 57, 647-6.
DOI
|
30 |
Okusaka T, Nakachi K, Fukutomi A, et al (2010). Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Brit J Cancer, 103, 469-74.
DOI
ScienceOn
|
31 |
Pasetto L, D'Andrea M, Falci C, et al (2007). Gemcitabine in advanced biliary tract cancers. Crit Rev Oncol/Hematol, 61, 230-42.
DOI
ScienceOn
|
32 |
Patel T (2002). Worldwide trends in mortality from biliary tract malignancies. BMC Cancer, 2, 10.
DOI
|
33 |
Patt Y, Hassan M, Lozano R, et al (2001). Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tree cancer. Clin Cancer Res, 7, 3375-80.
|
34 |
Park B, Kim Y, Park J, et al (2006). Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. J Gastroenterol Hepatol, 21, 999-1003.
DOI
ScienceOn
|
35 |
Park J, Oh S, Kim S, et al (2005). Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Japn J Clin Oncol, 35, 68.
DOI
ScienceOn
|
36 |
Penz C, Kornek G, Raderer M, et al (2001). Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol, 12, 183.
DOI
ScienceOn
|
37 |
Rau S, Autschbach F, Riedel HD, et al (2008). Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas. Eur J Clin Invest, 38, 134-42.
DOI
ScienceOn
|
38 |
Schunemann H, Jaeschke R, Cook D, et al (2006). An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med, 174, 605-14
DOI
ScienceOn
|
39 |
Sasaki T, Isayama H, Nakai Y, et al (2011). Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Investigational New Drugs, 29,1488-93.
DOI
ScienceOn
|
40 |
Smith G, Bukowski R, Hewlett J, et al (1984). Hepatic artery infusion of 5-fluorouracil and mitomycin C in cholangiocarcinoma and gallbladder carcinoma. Cancer, 54, 1513-6.
DOI
|
41 |
Thongprasert S, Napapan S, Charoentum C, et al (2005). Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol, 16, 279.
DOI
ScienceOn
|
42 |
Tsavaris N, Kosmas C, Gouveris P, et al (2004). Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs, 22, 193-8.
DOI
ScienceOn
|
43 |
Valencak J, Kornek G, Raderer M, et al (2000). Gemcitabine for the treatment of advanced biliary tract carcinomas: evaluation of two different dose regimens. Onkologie, 22, 498-501.
|
44 |
Valle J, Wasan H, Palmer DH, et al (2010). Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. New Engl J Med, 362, 1273-81.
DOI
ScienceOn
|
45 |
Von der Maase H, Sengelov L, Roberts J, et al (2005). Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol, 23, 4602.
DOI
ScienceOn
|
46 |
Von Delius S, Lersch C, Schulte-Frohlinde E, et al (2005). Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer, 5, 61.
DOI
ScienceOn
|
47 |
Wang LR, Zhang GB, Chen J, et al (2011). RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum. J Zhejiang Univ Sci B, 12, 174-9.
DOI
ScienceOn
|
48 |
Won HS, Lee MA, Chung ES, et al (2010). Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer. BMC Cancer, 19, 564.
|